Which are the causes of Congenital Fiber Type Disproportion?

Congenital Fiber Type Disproportion (CFTD) is a rare congenital myopathy primarily caused by genetic mutations that disrupt the development of muscle fibers. While the exact cause remains unknown in many cases, it is frequently linked to specific genetic variants, though the underlying biological mechanism is still a subject of active research.

What are the genetic causes of Congenital Fiber Type Disproportion?

Congenital Fiber Type Disproportion is often associated with mutations in genes involved in muscle structure and function. The most frequently identified genetic cause involves the ACTA1 gene, which provides instructions for making alpha-actin, a protein essential for muscle contraction. Other genes implicated in Congenital Fiber Type Disproportion include SELENON (formerly SEPN1), TPM3, and MYH7. In these instances, the disease is inherited, often in an autosomal recessive or autosomal dominant pattern, meaning the mutation is passed from parents to children.

Is the etiology of Congenital Fiber Type Disproportion fully understood?

Despite significant advancements in genomic sequencing, the etiology of Congenital Fiber Type Disproportion is not yet fully understood. In many patients, clinical testing fails to identify a causative gene mutation, suggesting that other, as-yet-undiscovered genes or complex regulatory mechanisms may be involved. Researchers are currently investigating how these genetic mutations lead to the characteristic "disproportion"—where type 1 muscle fibers are significantly smaller than type 2 fibers—to better understand the disease pathway.

What factors contribute to the development of this condition?

It is important to distinguish between the genetic *causes* of Congenital Fiber Type Disproportion and general risk factors. The primary cause is the inherited genetic mutation itself. Currently, there are no known environmental, autoimmune, or infectious triggers that cause Congenital Fiber Type Disproportion. Research into the condition focuses on the following areas:

• Identifying novel genetic variants through whole-exome sequencing.


• Studying muscle biopsy samples to analyze the protein expression patterns.


• Developing animal models to observe how specific mutations affect muscle fiber maturation.

Next steps

• Consult a neuromuscular specialist or pediatric neurologist for a formal evaluation.


• Seek a referral to a clinical geneticist for genomic testing and family counseling.


• Connect with the 17 members of the Congenital Fiber Type Disproportion community on DiseaseMaps.org to share experiences and resources.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• Orphanet: Congenital fiber type disproportion (ORPHA:2074)


• NIH GARD: Congenital fiber type disproportion


• OMIM: Congenital fiber type disproportion; CFTD (Entry #255310)


• PubMed: Clinical and genetic spectrum of congenital fiber type disproportion